Distribution · GCC · Announced 17 Apr 2025
Apex Pharma → CIGALAH Healthcare
Egypt's Apex Pharma signed a strategic partnership with Saudi distributor Saqqala Healthcare to distribute medicines made at its King Abdullah Economic City plant, its first outside Egypt, with technology transfer and local training.
Parties: Apex Pharma (Egypt) → CIGALAH Healthcare (Saudi Arabia)
- Deal type
- Distribution
- Value
- Undisclosed
- Territory
- Saudi Arabia
- Therapeutic area
- Multi-therapy
- Asset
- Chronic-disease portfolio made in KAEC (products not named)
- Announced
- 17 Apr 2025
Our analysis
Why this matters
Apex Pharma signed a strategic partnership with Saudi distributor CIGALAH Healthcare to distribute products manufactured at Apex's plant in King Abdullah Economic City (KAEC), reported on 17 April 2025. The focus is chronic conditions: cardiology, diabetes, psychiatric and neurological disorders, and urology. The partnership also covers knowledge and technology transfer and training of Saudi staff. The signing was attended by Sheikh Yasser Al-Nagi and Apex chairman Dr. Magdy Elba. Value and duration were not disclosed.
The KAEC plant is the first by an Egyptian drugmaker outside Egypt. Apex announced a SAR 300 million first-phase investment in December 2023, and Forbes Middle East reports the roughly $80 million factory was inaugurated in 2025.
The full analysis is free to read with a work email on this page.
Source: Souq Al Dawaa Saudi